Anne-Frédérique Turcotte1, Thomas Grenier-Larouche2,3, Roth-Visal Ung1, David Simonyan4, Anne-Marie Carreau2,3, André C Carpentier2,3, Fabrice Mac-Way1,5, Laetitia Michou1,5, André Tchernof1,5,6,7, Laurent Biertho6,8, Stefane Lebel6,8, Simon Marceau6,8, Claudia Gagnon9,10,11,12. 1. Endocrinology and Nephrology Unit, CHU de Québec Research Centre, 2705, Boulevard Laurier, Québec City, QC, G1V 4G2, Canada. 2. CHU de Sherbrooke Research Centre, Sherbrooke, Canada. 3. Department of Medicine, Université de Sherbrooke, Sherbrooke, Canada. 4. Clinical and Evaluative Research Platform, CHU de Québec-Université Laval Research Centre, Québec City, QC, Canada. 5. Department of Medicine, Université Laval, Québec City, Canada. 6. Québec Heart and Lung Institute Research Centre, Québec City, Canada. 7. Institute of Nutrition and Functional Foods, Université Laval, Quebec City, QC, Canada. 8. Department of Surgery, Université Laval, Québec City, Canada. 9. Endocrinology and Nephrology Unit, CHU de Québec Research Centre, 2705, Boulevard Laurier, Québec City, QC, G1V 4G2, Canada. claudia.gagnon@crchudequebec.ulaval.ca. 10. Department of Medicine, Université Laval, Québec City, Canada. claudia.gagnon@crchudequebec.ulaval.ca. 11. Québec Heart and Lung Institute Research Centre, Québec City, Canada. claudia.gagnon@crchudequebec.ulaval.ca. 12. Institute of Nutrition and Functional Foods, Université Laval, Quebec City, QC, Canada. claudia.gagnon@crchudequebec.ulaval.ca.
Abstract
BACKGROUND: This study evaluated early and medium-term changes in bone turnover markers, and their associations with weight loss, total bone mineral density (BMD), and hormonal changes after biliopancreatic diversion (BPD). METHODS: Ancillary study from a one-year prospective cohort of 16 individuals assessed before, 3 days, 3 and 12 months after BPD. Bone turnover markers (C-terminal telopeptide (CTX), intact osteocalcin (OC), sclerostin, and osteoprotegerin (OPG)) and several hormones were measured at each visit. Total BMD by DXA was assessed at baseline, 3 and 12 months after BPD. Three participants were lost to follow-up. RESULTS: CTX increased significantly at 3 days (+ 66%), 3 months (+ 219%), and 12 months (+ 295%). OC decreased at 3 days (- 19%) then increased at 3 months (+ 69%) and 12 months (+ 164%). Change in sclerostin was only significant between 3 days and 3 months (+ 13%), while change in OPG was significant between baseline and 3 days (+ 48%) and baseline and 12 months (+ 45%). CTX increase correlated negatively with weight loss at 3 (r = - 0.63, p = 0.009) and 12 months (r = - 0.58, p = 0.039), and total BMD decrease (r = - 0.67, p = 0.033) at 12 months. Change in insulin and adiponectin correlated with changes in bone turnover markers independently of weight loss. CONCLUSION: BPD causes an earlier and greater increase in bone resorption over bone formation markers and a decrease in total BMD. Sclerostin did not increase as expected following extensive weight loss. Changes in insulin and adiponectin seem to play a role in the activation of bone remodeling after BPD.
BACKGROUND: This study evaluated early and medium-term changes in bone turnover markers, and their associations with weight loss, total bone mineral density (BMD), and hormonal changes after biliopancreatic diversion (BPD). METHODS: Ancillary study from a one-year prospective cohort of 16 individuals assessed before, 3 days, 3 and 12 months after BPD. Bone turnover markers (C-terminal telopeptide (CTX), intact osteocalcin (OC), sclerostin, and osteoprotegerin (OPG)) and several hormones were measured at each visit. Total BMD by DXA was assessed at baseline, 3 and 12 months after BPD. Three participants were lost to follow-up. RESULTS:CTX increased significantly at 3 days (+ 66%), 3 months (+ 219%), and 12 months (+ 295%). OC decreased at 3 days (- 19%) then increased at 3 months (+ 69%) and 12 months (+ 164%). Change in sclerostin was only significant between 3 days and 3 months (+ 13%), while change in OPG was significant between baseline and 3 days (+ 48%) and baseline and 12 months (+ 45%). CTX increase correlated negatively with weight loss at 3 (r = - 0.63, p = 0.009) and 12 months (r = - 0.58, p = 0.039), and total BMD decrease (r = - 0.67, p = 0.033) at 12 months. Change in insulin and adiponectin correlated with changes in bone turnover markers independently of weight loss. CONCLUSION: BPD causes an earlier and greater increase in bone resorption over bone formation markers and a decrease in total BMD. Sclerostin did not increase as expected following extensive weight loss. Changes in insulin and adiponectin seem to play a role in the activation of bone remodeling after BPD.
Entities:
Keywords:
Bariatric surgery; Biliopancreatic diversion; Biochemical markers of bone turnover; Bone mineral density; Hormones
Authors: Dennis T Villareal; Luigi Fontana; Sai Krupa Das; Leanne Redman; Steven R Smith; Edward Saltzman; Connie Bales; James Rochon; Carl Pieper; Megan Huang; Michael Lewis; Ann V Schwartz Journal: J Bone Miner Res Date: 2015-09-24 Impact factor: 6.741
Authors: Keertik Fulzele; Ryan C Riddle; Douglas J DiGirolamo; Xuemei Cao; Chao Wan; Dongquan Chen; Marie-Claude Faugere; Susan Aja; Mehboob A Hussain; Jens C Brüning; Thomas L Clemens Journal: Cell Date: 2010-07-23 Impact factor: 41.582
Authors: Malou A H Nuijten; Thijs M H Eijsvogels; Valerie M Monpellier; Ignace M C Janssen; Eric J Hazebroek; Maria T E Hopman Journal: Obes Rev Date: 2021-10-19 Impact factor: 10.867